{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01007071: Phase 3 Interventional Completed Hypopituitarism
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02345070: Phase 2 Interventional Completed Idiopathic Pulmonary Fibrosis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03484923: Phase 2 Interventional Completed Melanoma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:cifurtilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03697304: Phase 2 Interventional Completed Neoplasm Metastasis
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tepoditamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:bifikafusp alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03358355: Phase 1/Phase 2 Interventional Completed Peripheral Artery Disease
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02988817: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02309320: Phase 1/Phase 2 Interventional Completed Respiratory Syncytial Virus Infection
(2014)
Source URL:
Class:
PROTEIN
